Pliant Therapeutics, Inc.

NASDAQ:PLRX

Biotechnology

Healthcare
$0.81 -3.39%

-$0.04 today

Market cap
$50.14M
Beta
1.21
P/E (TTM)
-0.6
EPS (TTM)
-$1.83
52W Low $1.09High $1.95

Volume 0.15M

Average 0.49M

Income Statement

Follow revenue through to earnings.

Revenue

$0.00

FY 2025 · Annual

Operating Income

-$150.07M

FY 2025 · Annual

Net Income

-$149.34M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue7.57M9.69M1.58M00
Cost of Revenue00001.7M
Gross Profit7.57M9.69M1.58M0(1.7M)
Gross Margin100.0%100.0%100.0%——
Research & Development77.55M96.94M127.8M169.31M109.16M
Selling, General & Admin27.56M39.95M57.93M59.06M47.22M
Operating Expenses105.11M136.89M185.73M228.37M148.38M
Depreciation & Amortization1.54M3.68M1.84M2.13M1.7M
EBITDA(95.73M)(118.85M)(158.23M)(205.16M)(145.09M)
EBITDA Margin-1264.2%-1227.1%-10014.4%——
Operating Income(97.54M)(127.2M)(184.15M)(228.37M)(150.07M)
Operating Margin-1288.1%-1313.4%-11654.7%——
Interest Income272K4.67M24.08M21.09M0
Interest Expense0791K1.27M3.02M2.56M
Other Income / Expenses272K3.88M22.81M18.06M729K
Income Before Tax(97.26M)(123.32M)(161.34M)(210.3M)(149.34M)
Pre-Tax Margin-1284.5%-1273.3%-10211.1%——
Income Tax Expense00000
Net Income(97.26M)(123.32M)(161.34M)(210.3M)(149.34M)
Net Margin-1284.5%-1273.3%-10211.1%——
EPS (Basic)(2.71)(2.94)(2.75)(3.47)(2.43)
EPS (Diluted)(2.71)(2.94)(2.75)(3.47)(2.43)
Weighted Avg Shares35.85M42.02M58.72M60.54M61.37M
Weighted Avg Shares (Diluted)35.85M42.02M58.72M60.54M61.37M

PLRX Earnings Waterfall · TTM

NASDAQ:PLRX · Revenue to Net Income

Key Ratios

EPS$-1.84
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-0.8
P/S Ratio0.0

Analysis

$0 of revenue converted into -$113.2M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.84, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
4Statement of changes in beneficial ownershipOct 2, 2026
3Initial statement of beneficial ownershipOct 2, 2026
SC 13GSC 13G filingAug 14, 2026
SC 13G/ASC 13G/A filingAug 14, 2026
8-KCurrent reportAug 11, 2026

How much revenue does PLRX generate?

Pliant Therapeutics, Inc. (PLRX) reported $0.00 of revenue in fiscal 2025.

Is PLRX profitable?

Pliant Therapeutics, Inc. (PLRX) reported -$149.34M of net income.